Harvard Combined Orthopaedics Residency Program, Boston, Massachusetts.
Department of Orthopaedic Surgery, Massachusetts General Hospital, Boston, Massachusetts.
J Bone Joint Surg Am. 2018 Dec 19;100(24):2095-2102. doi: 10.2106/JBJS.17.01400.
Cannabinoids are among the psychoactive substances considered as alternatives to opioids for the alleviation of acute pain. We examined whether self-reported marijuana use was associated with decreased use of prescription opioids following traumatic musculoskeletal injury.
Our analysis included 500 patients with a musculoskeletal injury who completed a survey about their marijuana use and were categorized as (1) never a user, (2) a prior user (but not during recovery), or (3) a user during recovery. Patients who used marijuana during recovery indicated whether marijuana helped their pain or reduced opioid use. Prescription opioid use was measured as (1) persistent opioid use, (2) total prescribed opioids, and (3) duration of opioid use. Persistent use was defined as the receipt of at least 1 opioid prescription within 90 days of injury and at least 1 additional prescription between 90 and 180 days. Total prescribed opioids were calculated as the total morphine milligram equivalents (MME) prescribed after injury. Duration of use was the interval between the first and last opioid prescription dates.
We found that 39.8% of patients reported never having used marijuana, 46.4% reported prior use but not during recovery, and 13.8% reported using marijuana during recovery. The estimated rate of persistent opioid use ranged from 17.6% to 25.9% and was not associated with marijuana use during recovery. Marijuana use during recovery was associated with increases in both total prescribed opioids (regression coefficient = 343 MME; 95% confidence interval [CI] = 87 to 600 MME; p = 0.029) and duration of use (coefficient = 12.5 days; 95% CI = 3.4 to 21.5 days; p = 0.027) compared with no previous use (never users). Among patients who reported that marijuana decreased their opioid use, marijuana use during recovery was associated with increased total prescribed opioids (p = 0.008) and duration of opioid use (p = 0.013) compared with never users.
Our data indicate that self-reported marijuana use during injury recovery was associated with an increased amount and duration of opioid use. This is in contrast to many patients' perception that the use of marijuana reduces their pain and therefore the amount of opioids used.
Therapeutic Level III. See Instructions for Authors for a complete description of levels of evidence.
大麻素是被认为可替代阿片类药物用于缓解急性疼痛的精神活性物质之一。我们研究了自我报告的大麻使用是否与创伤性肌肉骨骼损伤后处方类阿片药物使用减少有关。
我们的分析纳入了 500 名肌肉骨骼损伤患者,他们完成了一项关于大麻使用情况的调查,并分为(1)从不使用者,(2)既往使用者(但不在康复期间),或(3)康复期间使用者。在康复期间使用大麻的患者表明大麻是否有助于缓解疼痛或减少阿片类药物使用。处方类阿片药物使用的衡量标准为(1)持续使用阿片类药物,(2)总处方类阿片药物,和(3)阿片类药物使用持续时间。持续使用定义为在损伤后 90 天内至少收到 1 份阿片类药物处方,并且在 90 至 180 天期间至少收到另外 1 份处方。总处方类阿片药物的计算方法为损伤后开具的总吗啡毫克当量(MME)。使用时间是从第一份阿片类药物处方日期到最后一份阿片类药物处方日期之间的间隔。
我们发现,39.8%的患者报告从未使用过大麻,46.4%报告既往使用过大麻但不在康复期间,13.8%报告在康复期间使用过大麻。持续使用阿片类药物的估计率为 17.6%至 25.9%,与康复期间使用大麻无关。与从未使用过大麻的患者相比,康复期间使用大麻与总处方类阿片药物(回归系数=343 MME;95%置信区间[CI]:87 至 600 MME;p=0.029)和使用持续时间(系数=12.5 天;95%CI:3.4 至 21.5 天;p=0.027)的增加均相关。在报告大麻类药物减轻其阿片类药物使用的患者中,与从未使用者相比,康复期间使用大麻与总处方类阿片药物(p=0.008)和使用持续时间(p=0.013)的增加均相关。
我们的数据表明,自我报告的损伤康复期间使用大麻与阿片类药物使用量和持续时间的增加有关。这与许多患者认为使用大麻可减轻疼痛并因此减少阿片类药物使用量的观点相反。
治疗性 III 级。有关证据水平的完整描述,请参见作者说明。